Literature DB >> 10451512

Second-trimester pregnancy associated plasma protein-A levels are reduced in Cornelia de Lange syndrome pregnancies.

D A Aitken1, M Ireland, E Berry, J A Crossley, J N Macri, J Burn, J M Connor.   

Abstract

Maternal serum samples were collected from 19 pregnancies which resulted in the birth of a child with the classical Cornelia de Lange syndrome phenotype ascertained by careful clinical review. Using specific immunoassays, the serum levels of pregnancy associated plasma protein-A, free-beta human chorionic gonadotrophin and inhibin A were investigated. Pregnancy associated plasma protein-A was detectable in all cases but the levels were significantly reduced in second-trimester maternal serum from 18 affected pregnancies. Expressed as multiples of the median (MOM), the results ranged from 0.03 MOM to 0.71 MOM with an overall median value of 0.21 MOM (Mann-Whitney p<0.001). From these data it is possible to estimate a probability that any given level of this serum marker is associated with an affected pregnancy. One further sample taken in the first trimester from an affected pregnancy at 11 weeks' gestation had a normal pregnancy associated plasma protein-A level (1.22 MOM). Less markedly reduced levels were found for free beta human chorionic gonadotrophin and inhibin A. We conclude that second-trimester maternal serum pregnancy associated plasma protein-A measurements may be of value as an adjunct to ultrasonography in the prenatal diagnosis of Cornelia de Lange syndrome. A table of likelihood ratios is presented. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10451512

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  6 in total

Review 1.  Identification of a prenatal profile of Cornelia de Lange syndrome (CdLS): a review of 53 CdLS pregnancies.

Authors:  Dinah M Clark; Ilana Sherer; Matthew A Deardorff; Janice L B Byrne; Kathleen M Loomes; Malgorzata J M Nowaczyk; Laird G Jackson; Ian D Krantz
Journal:  Am J Med Genet A       Date:  2012-06-27       Impact factor: 2.802

2.  Mutational Screening and Prenatal Diagnosis in Cornelia de Lange syndrome.

Authors:  Usha Dave; Dhanlaxmi Shetty
Journal:  J Obstet Gynaecol India       Date:  2013-09-29

Review 3.  Unique occurrence of Brachmann-de Lange syndrome in a fetus whose mother presented with a diffuse large B-cell lymphoma.

Authors:  Christiane Schiffer; Monika Schiesser; Jutta Lehr; Gholamali Tariverdian; Dieter Glaeser; Heinz Gabriel; Gregor Mikuz; Consolato Sergi
Journal:  Pathol Oncol Res       Date:  2007-10-07       Impact factor: 3.201

4.  Down syndrome serum screening also identifies an increased risk for multicystic dysplastic kidney, two-vessel cord, and hydrocele.

Authors:  Jodi D Hoffman; Diana W Bianchi; Lisa M Sullivan; Brenda L Mackinnon; Jamie Collins; Fergal D Malone; T Flint Porter; David A Nyberg; Christine H Comstock; Radek Bukowski; Richard L Berkowitz; Susan J Gross; Lorraine Dugoff; Sabrina D Craigo; Ilan E Timor-Tritsch; Stephen R Carr; Honor M Wolfe; Mary E D'Alton
Journal:  Prenat Diagn       Date:  2008-12       Impact factor: 3.050

5.  Dental findings in Cornelia de Lange syndrome.

Authors:  Aslihan Soyal Toker; Sinan Ay; Hasan Yeler; Ilhan Sezgin
Journal:  Yonsei Med J       Date:  2009-04-30       Impact factor: 2.759

6.  Clinical and genetic study of 20 patients from China with Cornelia de Lange syndrome.

Authors:  Mingyan Hei; Xiangyu Gao; Lingqian Wu
Journal:  BMC Pediatr       Date:  2018-02-16       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.